Compare Repligen Corporation Common Stock (RGEN) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Zeta Global Holdings Corp — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while Zeta Global Holdings Corp trades at $31.6 (market cap $8.48B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Zeta Global Holdings Corp is more actively traded (4,868,041 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Zeta Global Holdings Corp for 19 Days on average.
| RGEN | ZETA | |
|---|---|---|
Market Cap | $11.14B | $8.48B |
Volume | 1,259,263 | 4,868,041 |
Sector | Health | Technology |
52-Week High | $194.57 | $33.80 |
52-Week Low | $102.87 | $14.55 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $11.02B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Zeta Global (ZETA) trades at $33.80, up 0.87% today, showing strong momentum with seven consecutive quarters of earnings beats. The stock exhibits a bullish technical setup with moving averages supporting the uptrend, though RSI levels suggest potential overbought conditions. Revenue growth accelerated to $1.3 billion in 2025 with improving margins, while analyst consensus remains strongly positive with 76% buy ratings and a $37.09 price target. Recent expansion into the UK market and AI platform adoption continue to drive investor optimism.
ZETA presents a compelling growth story with accelerating revenue and expanding customer base, though negative net margins and elevated valuation multiples warrant caution. The stock's proximity to 52-week highs combined with strong institutional support suggests continued upside potential, but investors should monitor margin improvement and competitive pressures in the AI marketing technology space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
